Biopharma companies, BARDA call for more clarity on FDA’s new platform tech proposal

Roivant re­port­ed Mon­day morn­ing that a pro­gram li­censed from Pfiz­er failed a Phase II lu­pus tri­al and that it would end de­vel­op­ment in the con­di­tion.

Ap­n­imed named a new chief com­mer­cial of­fi­cer on Mon­day, tap­ping Gra­ham Goodrich, a vet­er­an bio­phar­ma mar­ket­ing ex­ec­u­tive, to start build­ing out a team to com­mer­cial­ize